Mébutate D'ingénol
Mébutate D'ingénol Uses, Dosage, Side Effects, Food Interaction and all others data.
Mébutate D'ingénol was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including warts and cancer. PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations.
The pharmacodynamics of ingenol mebutate in producing cell death in actinic keratosis is unknown.
| Trade Name | Mébutate D'ingénol |
| Generic | Ingenol mebutate |
| Ingenol mebutate Other Names | Ingenol mebutate, Ingenol mebutato, Ingenoli mebutas, Mébutate d'ingénol, Mebutato de ingenol |
| Type | |
| Formula | C25H34O6 |
| Weight | Average: 430.541 Monoisotopic: 430.235538815 |
| Protein binding | There is no plasma protein binding quantity since ingenol mebutate is a topical treatment |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Mébutate D'ingénol is a topical agent used for the treatment of actinic keratosis.
For the topical treatment of actinic keratosis.
Mébutate D'ingénol is also used to associated treatment for these conditions: Actinic Keratosis (AK)
How Mébutate D'ingénol works
The exact mechanism of action of ingenol mebutate in actinic keratosis is unknown. It is presumed to involve primary necrosis then neutrophil-mediated inflammation and antibody-dependent cell death of residual disease cells. Additionally in early studies, PEP005 was shown to be an effective activator of PKC-delta and PKC-delta translocation into nucleus and membranes. PEP005 also downregulates the expression and activity of PKC-alpha. PEP005 induced modulation of PKCs leads to Ras/Raf/MAPK and p38 activation and AKT/PKB inhibition.
Toxicity
The most common adverse reactions are local skin reactions at the application site, headache, periorbital edema,and nasopharyngitis.
Food Interaction
- Take with or without food.
Volume of Distribution
There is no volume of distribution quantity since ingenol mebutate is a topical treatment.
Elimination Route
Since ingenol mebutate is a topical treatment, the systemic absorption is less than 0.1 ng/mL.
Half Life
There is no half-life quantity since ingenol mebutate is a topical treatment.
Clearance
There is no clearance quantity since ingenol mebutate is a topical treatment.
Elimination Route
There is no route of elimination since ingenol mebutate is a topical treatment.
Innovators Monograph
You find simplified version here Mébutate D'ingénol
